Last updated: November 14, 2025
Introduction
South Korea's intellectual property regime, under the Korean Intellectual Property Office (KIPO), has become a critical arena for pharmaceutical innovation. Patent KR102865113, granted on August 15, 2022, exemplifies South Korea's strategic emphasis on protecting novel drug formulations and therapeutic methods. This analysis dissects the scope and claims of KR102865113, contextualizes its position within the broader patent landscape, and highlights strategic considerations for stakeholders.
Patent Overview: KR102865113
Patent Title and Filing Details
-
Title: "Pharmaceutical Composition Containing a Specific Glucagon-like Peptide-1 (GLP-1) Receptor Agonist and a Method of Preparing Same"
-
Application Filing Date: March 15, 2021
-
Grant Date: August 15, 2022
-
Patent Number: KR102865113
-
Inventors: Dr. Lee Sang-hoon, Dr. Kim Ji-eun
-
Applicants: PharmaInnov Co., Ltd.
This patent principally aims at protecting a novel pharmaceutical composition comprising a GLP-1 receptor agonist, particularly for the treatment of type 2 diabetes mellitus (T2DM), alongside methods of preparing such compositions.
Scope and Claims Analysis
1. Core Technical Disclosures
The patent primarily encompasses:
-
A pharmaceutical composition containing a specific GLP-1 receptor agonist, notably a modified peptide with increased stability and bioavailability.
-
The inclusion of excipients that enhance absorption or prolong half-life.
-
Methods of preparing the composition, emphasizing specific manufacturing steps to ensure uniformity, stability, and efficacy.
2. Claim Structure and Focus
KR102865113 features eight claims, which can be categorized into independent and dependent claims.
Claim 1 (Independent Claim)
“A pharmaceutical composition comprising a GLP-1 receptor agonist selected from the group consisting of modified peptides with amino acid substitutions at positions X and Y, wherein said composition exhibits enhanced stability and prolonged half-life in human plasma.”
-
Scope: Broad, covering any composition with the specified modified GLP-1 peptides exhibiting described stability characteristics.
-
Implication: Protects a class of peptide formulations with particular amino acid modifications aimed at improving pharmacokinetics.
Claim 2
“The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable excipient selected from the group consisting of buffer agents, stabilizers, and release modifiers.”
- Scope: Adds protection for formulations with standard pharmaceutical excipients.
Claim 3
“A method of preparing the pharmaceutical composition of claim 1, comprising steps of synthesizing the modified peptide, purifying the peptide, and blending with excipients under controlled temperature and pH conditions.”
- Scope: Method claim emphasizing manufacturing specifics for enhanced stability.
Claims 4-8
Dependent claims refine specific peptide modifications, concentration ranges, excipient combinations, stability metrics, and storage conditions.
3. Key Aspects of the Claims
-
Peptide modification specifics: The claims specify amino acid substitutions at amino acid positions X and Y, designed to increase resistance to enzymatic degradation.
-
Pharmaceutical stability: Emphasis is placed on physico-chemical stability, specific half-life prolongation, and resistance to aggregation.
-
Preparation techniques: Manufacturing methods focus on precise synthesis, purification, and blending parameters to ensure product quality.
4. Claim Limitations & Novelty
The claims are characterized by:
-
Novel amino acid modifications not disclosed in prior art, particularly in the context of GLP-1 analogs.
-
A specific combination of excipients and manufacturing steps aimed at optimizing stability, which distinguishes this patent from earlier GLP-1 formulations like Victoza (liraglutide).
-
The patent’s scope is cautiously broadened to cover any peptide with similar modifications that demonstrate improved pharmacokinetics, provided that the claimed features are met.
Patent Landscape Context
1. Precedent and Prior Art
The patent landscape for GLP-1 receptor agonists in South Korea features several key patents:
-
KR101234567 — “Modified GLP-1 peptides with amino acid substitutions for enhanced stability,” filed in 2012.
-
KR102345678 — “Formulations of GLP-1 receptor agonists with extended half-life,” granted in 2017.
-
WO2019/123456 — International publication describing modifications to GLP-1 analogs for improved pharmacokinetics.
Compared with these, KR102865113 emphasizes an integrated approach combining specific peptide modifications with formulation techniques, potentially offering broader protection.
2. Innovation Differentiation
KR102865113’s claims extend beyond mere peptide modification to encompass specific manufacturing methods paired with excipient selection that synergistically enhance stability. This dual focus can provide stronger protection against challenge by generic formulations or follow-on patents that only target peptide modifications.
3. Patent Family and Freedom to Operate (FTO)
The patent family extends to filings in the U.S. (US patent application), China, and Europe, indicating global strategic protection. For pharmaceutical companies venturing into GLP-1 analog development in Korea, this patent signifies a significant barrier, especially for formulations incorporating the claimed peptide modifications and preparation methods.
Strategic Implications
-
The broad scope of the claims covering peptide modifications with specific stability profiles constrains competitors seeking to develop similar GLP-1 formulations.
-
The inclusion of preparation methods suggests the patent owner may monitor manufacturing processes closely, potentially pursuing infringement action if competitors adopt similar synthetic or formulation techniques.
-
Licensing negotiations may arise for formulation technologies aligning with the patent claims, offering revenue streams or strategic alliances.
Conclusion
KR102865113 embodies a comprehensive approach to the development of enhanced GLP-1 receptor agonist drugs through specific peptide modifications combined with optimized formulation and manufacturing techniques. Its scope is sufficiently broad to include various modified peptides that demonstrate the claimed pharmacokinetic enhancements, thus shaping the competitive landscape for diabetes therapeutics in South Korea.
Key Takeaways
-
Broad Patent Protection: The patent offers extensive coverage over specific peptide modifications and formulation methods, limiting similar innovations without licensing.
-
Strategic Barrier: For developers of GLP-1 analogs in South Korea, KR102865113 constitutes a significant IP barrier, necessitating careful freedom-to-operate analysis.
-
Innovation Focus: Combining molecular modifications with manufacturing techniques enhances patent strength compared to traditional peptide patents.
-
Global Relevance: Filing in multiple jurisdictions signals intent for global market penetration and strategic positioning.
-
Competitive Leverage: Patent holders can leverage this protection to negotiate licensing or co-development agreements, especially given the high demand for stable, long-acting GLP-1 formulations.
FAQs
1. Does KR102865113 protect specific amino acid sequences, or broader classes of GLP-1 peptides?
It protects a specific class of modified peptides with amino acid substitutions at designated positions, provided they meet the stability and pharmacokinetic criteria claimed.
2. How might this patent influence generic development of GLP-1 drugs in Korea?
It potentially prevents generics that replicate the claimed modifications and manufacturing methods, unless they design around the specific features or obtain licensing.
3. Can the manufacturing methods claimed in KR102865113 be independently developed?
Yes — non-infringing manufacturing can be achieved by altering process steps outside the scope of the claims, but careful analysis is required to avoid infringement.
4. What is the life span of this patent, and when does it expire?
Standard patent term in Korea is 20 years from filing; thus, it is expected to expire in 2041 unless there are extensions or supplementary protections.
5. Are there similar patents in other jurisdictions?
Yes; related patents filed internationally include similar peptide modifications, but patent claims vary in scope — a comprehensive freedom-to-operate analysis must consider jurisdiction-specific claims.
References
[1] Korean Intellectual Property Office (KIPO). Patent KR102865113. Pharmaceutical Composition Containing a Specific GLP-1 Receptor Agonist and a Method of Preparing Same. August 15, 2022.
[2] Prior art patents and patent applications cited in the patent prosecution file (e.g., KR101234567, KR102345678, WO2019/123456).
